Talaris initiates FREEDOM-1 clinical trial for FCR001 in LDKT recipients
Talaris Therapeutics has initiated the phase 3 FREEDOM-1 clinical trial to evaluate its investigational, allogeneic cell therapy FCR001 in living donor kidney transplant (LDKT) recipients. ... Read More